RD-1302 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RD-1302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RD-1302 overview
RD13-02 is under development for the treatment of CD7 positive relapsed or refractory T-acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL), and acute myelogenous leukemia (AML). The therapeutic candidate comprises T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting CD7 expressing cancer cells. It is administered through parenteral route.
Nanjing Bioheng Biotech overview
Nanjing Bioheng Biotech Co., Ltd., is engaged in developing cell therapy products and universal CAR-T product. The company is headquartered in China.
For a complete picture of RD-1302’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
